Last reviewed · How we verify
2%lidocaine with 1:80.000 epinphrine
2%lidocaine with 1:80.000 epinphrine is a Small molecule drug developed by University of Baghdad. It is currently FDA-approved.
At a glance
| Generic name | 2%lidocaine with 1:80.000 epinphrine |
|---|---|
| Sponsor | University of Baghdad |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 2%lidocaine with 1:80.000 epinphrine CI brief — competitive landscape report
- 2%lidocaine with 1:80.000 epinphrine updates RSS · CI watch RSS
- University of Baghdad portfolio CI
Frequently asked questions about 2%lidocaine with 1:80.000 epinphrine
What is 2%lidocaine with 1:80.000 epinphrine?
2%lidocaine with 1:80.000 epinphrine is a Small molecule drug developed by University of Baghdad.
Who makes 2%lidocaine with 1:80.000 epinphrine?
2%lidocaine with 1:80.000 epinphrine is developed and marketed by University of Baghdad (see full University of Baghdad pipeline at /company/university-of-baghdad).
What development phase is 2%lidocaine with 1:80.000 epinphrine in?
2%lidocaine with 1:80.000 epinphrine is FDA-approved (marketed).